Securing an export location – for an internationally connected Switzerland

With exports valued at 105.5 billion Swiss francs ($130.2 billion) and a 38.5% share of total exports, the pharmaceutical industry is Switzerland's most important export sector.

Three-quarters of pharmaceutical exports go to the European Union or the USA. However, there is considerable uncertainty about how we will continue our relations with our two most important trading partners, sys the Swiss pharma trade group Interpharma. To ensure Switzerland's long-term competitiveness as a research and production location, it needs stability and planning security.

Regulating the relationship with the EU is in its own hands. The Bilateral Agreements III can create the necessary framework to ensure legal certainty and predictability in the long term – both essential for internationally active companies, the Interpharma said.